Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations sending the company’s stock price spiralling. Despite hitting its ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting ...

LONDON, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said ...

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.

Few (if any) companies have a more attractive pipeline in this field than Novo Nordisk. True, one of the drugmaker's leading candidates, CagriSema, recently failed to impress investors in a phase ...